This manuscript discusses the challenges of managing dyslipidemia in pregnancy, rheumatoid arthritis, HIV, chronic liver disease, elderly patients, and COVID-19, highlighting unique treatment considerations and limited available data.

Bariatric surgery led to significant weight loss and metabolic improvements in adolescents with severe obesity after failed lifestyle intervention, outperforming conservative treatment in a one-year randomized trial.

Semaglutide (2.4 mg) significantly reduces body weight in overweight/obese individuals without diabetes, with a 12.1% relative weight loss. Gastrointestinal adverse events are common but mostly mild. Long-term efficacy and safety are confirmed.

The GDF15-GFRAL pathway regulates metabolism, appetite, and obesity. Targeting this axis offers a promising strategy for obesity treatment, with minimal impact on muscle mass, though challenges remain in its application.

This review explores GLP-1 receptor-binding medications for obesity, assessing their mechanisms, efficacy, and safety, highlighting key treatments like retatrutide, tirzepatide, and semaglutide, with an emphasis on long-term outcomes.

Incretin-mimetic drugs for obesity may cause muscle loss, impacting health. Adequate protein, micronutrients, and resistance training are essential to preserve muscle mass, optimize therapy, and minimize risks in patients.

Obesity pharmacotherapy has evolved with six FDA-approved medications for long-term weight management, recommended for individuals with BMI ≥30 or ≥27 with comorbidities, alongside lifestyle modifications for effective treatment.

This review highlights gender differences in obesity prevalence, contributing factors, clinical complications, psychological challenges, and responses to treatments, including new anti-obesity drugs, emphasizing the need for gender-specific approaches.

Obesity in untreated early rheumatoid arthritis reduces treatment response likelihood across therapies, with higher disease activity despite similar baselines, highlighting BMI's impact on clinical outcomes over 48 weeks.

Pre-pregnancy BMI, gestational weight gain, and interpregnancy BMI influence pregnancy complications like HDP, GDM, and preterm birth, affecting both maternal cardiovascular risk and offspring health. Racial/genetic factors should guide weight management.

This review highlights the need for more randomized controlled trials evaluating tailored weight management interventions for Hispanic men, with some short-term efficacy observed, particularly in family support and language access strategies.

Pediatric obesity treatment faces challenges such as stigma, lifestyle changes, social determinants, and healthcare access. A comprehensive, team-based approach is needed to address these barriers and create effective solutions.

Extreme obesity (BMI ≥ 50 kg/m²) requires effective management, including sleeve gastrectomy, very-low-calorie diets, or bariatric surgery. Nonstandard techniques and anti-obesity drugs may improve outcomes, but more research is needed.

Psychological treatments are first-line for eating disorders, but efficacy remains limited. Pharmacologic options are scarce. Emerging adaptive treatment designs offer clinical insights and potential models for improved future therapies.

A study on 29 children with obesity and NAFLD found that vitamin E enriched with tocotrienol (TRF) reduced DNA damage, inflammatory cytokines, and liver markers, suggesting its potential as a safe treatment for NAFLD.

MASLD impacts bone health, reducing BMD and increasing fragility fractures in adults, especially elderly Asian men, due to disrupted bone remodeling, insulin resistance, inflammation, and comorbidities like obesity and diabetes.

Pediatric MASLD, affecting up to 40% of children with obesity, primarily responds to lifestyle interventions like diet and exercise; studies highlight benefits but lack consensus on optimal approaches, warranting further research.

Obesity significantly impacts female reproductive health, contributing to conditions like PCOS, menstrual disturbances, and infertility. Weight loss strategies and IVF efficacy are influenced by obesity, involving hormonal and inflammatory disruptions.

This review discusses the intersection of type 1 diabetes and obesity, highlighting their bidirectional relationship, biopsychosocial impacts, and therapeutic approaches, including exercise, nutrition, pharmacotherapy, and bariatric surgery.